v3.26.1
Product Sales year-on-year analysis: H1 2026 (Tables)
6 Months Ended
Jun. 30, 2026
Product Sales year-on-year analysis: H1 2026  
Product Sales year-on-year analysis: H1 2026

World

US

Emerging Markets

Europe

Established RoW

For the half year ended 30 June

Change

Change

Change

Change

Change

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

Tagrisso

 

3,775

8

6

1,579

10

1,048

4

769

17

8

379

(1)

2

Imfinzi

 

3,548

31

29

2,008

28

398

35

32

781

45

34

361

15

20

Calquence

1,944

19

16

1,286

18

137

33

26

442

20

11

79

9

7

Lynparza

1,610

3

(1)

659

(4)

343

6

(1)

480

13

4

128

1

3

Enhertu

662

55

49

440

51

47

132

41

28

90

n/m

n/m

Zoladex

607

7

2

9

4

480

9

4

81

13

5

37

(16)

(18)

Truqap

431

43

41

306

21

35

n/m

n/m

65

n/m

n/m

25

98

n/m

Imjudo

160

(6)

(7)

100

10

13

9

8

28

22

13

19

(22)

(19)

Datroway

5

n/m

n/m

5

n/m

n/m

Etcamah

3

n/m

n/m

3

n/m

n/m

Other Oncology

 

203

(6)

(8)

4

(1)

141

(3)

(6)

8

(19)

(30)

50

(12)

(7)

Oncology

 

12,948

17

14

5,951

15

3,043

16

11

2,786

26

16

1,168

9

11

Farxiga

3,997

(5)

(11)

668

(17)

1,618

(6)

(13)

1,586

10

1

125

(45)

(45)

Crestor

685

8

4

18

(23)

612

12

8

1

n/m

80

54

(16)

(13)

Brilinta

186

(64)

(66)

16

(94)

142

4

24

(78)

(80)

4

(35)

(33)

Lokelma

 

419

28

26

164

14

93

47

41

87

56

44

75

17

23

Seloken

 

337

9

5

326

9

5

9

5

5

2

(1)

(8)

roxadustat

 

57

(62)

(64)

57

(62)

(64)

Wainua

121

44

44

109

33

4

n/m

n/m

7

n/m

n/m

1

n/m

n/m

Baxfendy

3

n/m

n/m

2

n/m

1

n/m

n/m

Other CVRM

 

206

(25)

(28)

(9)

n/m

145

5

1

42

(45)

(49)

28

(14)

(11)

CVRM

 

6,011

(8)

(12)

968

(28)

2,998

(2)

(7)

1,756

3

(5)

289

(27)

(25)

Symbicort

 

1,418

(1)

(4)

545

(9)

417

4

296

9

1

160

(5)

(8)

Fasenra

 

1,053

14

12

594

7

92

75

69

258

13

4

109

31

33

Breztri

699

20

17

309

5

208

34

27

127

45

34

55

24

24

Tezspire

321

62

54

44

n/m

n/m

202

57

46

75

39

43

Saphnelo

380

25

24

318

20

11

67

63

36

71

57

15

40

44

Pulmicort

269

2

(3)

3

(6)

219

5

31

(9)

(16)

16

(16)

(17)

Airsupra

 

87

24

23

78

12

9

n/m

n/m

Other R&I

 

130

(18)

(21)

15

(73)

55

(22)

(26)

57

97

88

3

(1)

(4)

R&I

 

4,357

11

8

1,862

1

1,055

16

11

1,007

26

17

433

13

13

Beyfortus

71

(44)

(44)

61

(40)

9

(62)

(63)

1

(38)

(29)

FluMist

26

n/m

n/m

(2)

n/m

1

n/m

n/m

27

n/m

n/m

Other ID

92

(43)

(47)

(1)

(40)

70

(42)

(46)

16

(39)

(46)

7

(60)

(58)

ID*

 

189

(37)

(40)

58

(42)

71

(41)

(45)

25

(51)

(55)

35

21

18

Ultomiris

 

2,584

16

14

1,398

10

190

68

65

605

22

12

391

13

17

Soliris

778

(20)

(22)

414

(27)

248

10

6

61

(46)

(50)

55

(20)

(21)

Strensiq

1,053

41

40

859

47

65

30

13

68

20

10

61

10

14

Koselugo

 

347

26

21

94

(11)

115

52

42

99

39

28

39

74

80

Other Rare Disease

149

32

25

58

7

34

73

47

41

20

10

16

n/m

n/m

Rare Disease

4,911

13

11

2,823

9

652

35

28

874

13

4

562

13

16

Other Medicines

480

(6)

(8)

42

6

359

(9)

(11)

39

12

8

40

(3)

(3)

Total Medicines

 

28,896

8

5

11,704

6

8,178

8

3

6,487

16

7

2,527

4

6

The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.

* ID: Infectious Disease